Biotech giant Amgen is hoping to bolster its cancer drug pipeline by buying fellow drug developer Micromet Inc. for $1.16 billion.
By Tiffany Hsu, Los Angeles Times
Thu, 01/26/2012 - 10:06am
Biotech giant Amgen is hoping to bolster its cancer drug pipeline by buying fellow drug developer Micromet Inc. for $1.16 billion.